Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 13.74B P/E 41.42 EPS this Y -12.70% Ern Qtrly Grth -55.20%
Income 673.24M Forward P/E 7.90 EPS next Y 11.20% 50D Avg Chg -3.00%
Sales 2.24B PEG 2.24 EPS past 5Y 34.59% 200D Avg Chg -16.00%
Dividend 2.00% Price/Book 2.31 EPS next 5Y 3.20% 52W High Chg -31.00%
Recommedations 2.00 Quick Ratio 9.35 Shares Outstanding 448.13M 52W Low Chg 5.00%
Insider Own 13.05% ROA 3.45% Shares Float 387.70M Beta 0.46
Inst Own 72.75% ROE 10.53% Shares Shorted/Prior 14.19M/14.28M Price 30.65
Gross Margin 55.46% Profit Margin 30.09% Avg. Volume 2,432,067 Target Price 44.83
Oper. Margin 50.19% Earnings Date Nov 6 Volume 1,837,290 Change -0.81%
About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc News
11/14/24 Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
11/13/24 Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues
11/07/24 Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
11/07/24 Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions
11/07/24 Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
11/06/24 Royalty Pharma Reports Third Quarter 2024 Results
11/04/24 Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
11/04/24 Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
11/03/24 Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks
10/16/24 Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
10/14/24 Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21
10/11/24 Royalty Pharma Declares Fourth Quarter 2024 Dividend
10/09/24 Royalty Pharma PLC (RPRX) Q2 2024 Earnings Call Highlights: Surpassing Growth Expectations and ...
10/09/24 Royalty Pharma plc (RPRX): Among The Stocks With Biggest Upside Potential According to Hedge Funds
09/06/24 Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
09/03/24 Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
09/03/24 Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
08/28/24 Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
08/26/24 Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’
08/17/24 Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now?
RPRX Chatroom

User Image Evangeline_Roman Posted - 1 day ago

$RPRX $GMAB LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image ViktorSinclair Posted - 1 day ago

$RPRX Why is this such a shitty stock?

User Image UncleStock Posted - 3 days ago

$RPRX $ZTS $JNJ $OGN suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image Stocksrunner Posted - 4 days ago

Weekend Watch $RPRX close to its support at $25.58, with a strong RSI of 30.44 signaling it’s near oversold levels. The elevated volume suggests potential accumulation at this level. A bounce could take the stock back toward resistance.

User Image RobotMumba100 Posted - 6 days ago

$LNTH we need to thanks the new Idi0t at the white house....$temp $ebs $elv $RPRX

User Image STOCKPICKERTRADER Posted - 6 days ago

$RPRX picked up some shares to bottom fish this morning on a position

User Image Estimize Posted - 1 week ago

Wall St is expecting 1.00 EPS for $RPRX Q4 [Reporting 02/12 BMO] http://www.estimize.com/intro/rprx?chart=historical&metric_name=eps&utm_co

User Image cristhm Posted - 1 week ago

$RPRX back to this..

User Image UncleStock Posted - 1 week ago

$RPRX $ZTS $JNJ $OGN suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image ChristaBoarts Posted - 1 week ago

$RPRX Impact BioMedical’s commitment to pioneering healthcare breakthroughs signals promising future returns.

User Image UncleStock Posted - 1 week ago

$RPRX $ZTS $JNJ $OGN suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image dloeb Posted - 1 week ago

$RPRX added shares

User Image STOCKPICKERTRADER Posted - 1 week ago

@Fixaleg waiting for that 26.65-26.80 area to continue with more $RPRX but definitely will continue to increase in here

User Image Fixaleg Posted - 1 week ago

$RPRX once back above VWAP at 26.49 then POC around 27.20 next area target

User Image Fixaleg Posted - 1 week ago

$RPRX adding more after 26.56 area hit

User Image STOCKPICKERTRADER Posted - 1 week ago

$RPRX looks to have based for a climb out following the good earnings results and raised outlook. Accumulating shares for a position from here

User Image STOCKPICKERTRADER Posted - 1 week ago

@OpenOutcrier Well, they $RPRX raised guidance and gets that MM gut punch like $PFE did... time will tell as they say!

User Image Fixaleg Posted - 1 week ago

$RPRX picked up shares here - company just beat on earnings report and has added 2 new royalty deals in past 3-5 days and near 52-week lows with sluggish sector - for now. Undervalued seriously imho

User Image dloeb Posted - 1 week ago

$RPRX adding shares

User Image STOCKPICKERTRADER Posted - 1 week ago

$RPRX picked up some shares to build position

User Image Fixaleg Posted - 2 weeks ago

@STOCKPICKERTRADER picked up some shares to try and bottom fish here on the positive earnings report and raise. Action reminds me of the $PFE result on earnings beat and raise... go fish! $RPRX

User Image dloeb Posted - 2 weeks ago

$RPRX picked up some shares here to start a position

User Image STOCKPICKERTRADER Posted - 2 weeks ago

$RPRX starting position on earnings beat and raise

User Image OpenOutcrier Posted - 2 weeks ago

$RPRX (+2.7% pre) Royalty Pharma reports Q3 results, raises FY guidance https://ooc.bz/l/47050

User Image DonCorleone77 Posted - 2 weeks ago

$RPRX $SNDX Royalty Pharma enters $350M synthetic royalty funding agreement with Syndax Royalty Pharma (RPRX) and Syndax Pharmaceuticals (SNDX) announced that Royalty Pharma has entered into a $350M synthetic royalty funding agreement with Syndax based on U.S. net sales of Niktimvo. Under the terms of the agreement, Syndax received an upfront payment of $350M in exchange for a 13.8% royalty on U.S. net sales of Niktimvo. Royalty payments to Royalty Pharma will cease upon reaching a multiple of 2.35x.

User Image tradingtwenty Posted - 2 weeks ago

Top 5 trending stocks in the past 24 hours (based on 5 minute intervals): $VKTX 276 🔥 $PLTR 276 $TNYA 265 $RPRX 263 $VRT 214 Link: https://tradingtwenty.com/dashboard/trending/past

User Image Eddie_Blake Posted - 2 weeks ago

$RPRX $GMAB MYNZ +10.91% PM LFG, unusually high volume activity last week, apx 30% more than average. 👇😘🚀 This stock may see the last time this price per share PT $5+ 🚀 HUGE PRs drop incoming before the Nov 13 meeting, so compliance is coming—no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead.

User Image UncleStock Posted - 10/28/24

$RPRX $ZTS $JNJ $MRK suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

User Image Estimize Posted - 10/28/24

Wall St is expecting 9.41% YoY revenue growth for $RPRX in Q3, down from 11.60% in Q2 [Reporting 11/06 BMO] http://www.estimize.com/intro/r

User Image UncleStock Posted - 10/23/24

$RPRX $ZTS $JNJ $MRK suggested for $DRG US ARCA Pharmaceutical - value screen: https://zpr.io/tykPs

Analyst Ratings
Goldman Sachs Buy Aug 14, 24
Morgan Stanley Overweight Jul 11, 24
UBS Neutral Jun 3, 24
B of A Securities Buy Apr 12, 24
JP Morgan Overweight Feb 20, 24
Goldman Sachs Buy Feb 20, 24
Morgan Stanley Overweight Nov 9, 23
Morgan Stanley Overweight Oct 11, 23
Morgan Stanley Overweight Aug 9, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
RIGGS RORY B Director Director Jan 02 Sell 27.95 470,000 13,136,500 20,099 01/04/24
Avara Management Ltd 10% Owner 10% Owner Dec 27 Sell 28.11 251,592 7,072,251 2,543,323 12/29/23
Coyne Terrance P. EVP & CFO EVP & CFO Aug 09 Sell 30.73 75,000 2,304,750 790,000 08/11/23
Coyne Terrance P. EVP & CFO EVP & CFO Jul 12 Sell 31 75,000 2,325,000 865,000 07/14/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Jun 02 Sell 33.63 192,221 6,464,392 30,000 06/06/23
Legorreta Pablo G. CEO, Chairman of the.. CEO, Chairman of the Board May 24 Buy 32.2496 150,000 4,837,440 380,000 05/24/23
RIGGS RORY B Director Director May 22 Sell 32.82 1,750,000 57,435,000 6,762 05/22/23
RIGGS RORY B Director Director Mar 29 Sell 36.6 139,950 5,122,170 1,456,762 03/30/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Mar 28 Sell 37.04 112,779 4,177,334 212,221 03/30/23
Lloyd George W. EVP, Investments & C.. EVP, Investments & CLO Feb 23 Sell 37.2663 25,000 931,658 325,000 02/27/23
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Feb 22 Sell 37.2965 23,333 870,239 46,667 02/24/23
RIGGS RORY B Director Director Dec 09 Sell 42.02 60,000 2,521,200 96,712 12/13/22
Coyne Terrance P. EVP & CFO EVP & CFO Nov 02 Sell 43.0629 5,500 236,846 964,500 11/04/22
Giuliani Mario Germano Director Director Sep 28 Sell 41.05 32,593 1,337,943 8,077,140 09/30/22
Giuliani Mario Germano Director Director Sep 22 Sell 41.1681 211,380 8,702,113 8,109,733 09/26/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 20 Sell 41.0201 267,815 10,985,798 21,426,170 09/22/22
Giuliani Mario Germano Director Director Sep 16 Sell 41.61 387,171 16,110,185 22,657,815 09/20/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 16 Sell 41.61 387,171 16,110,185 21,693,985 09/20/22
RIGGS RORY B Director Director Sep 14 Sell 42.31 100,000 4,231,000 276,712 09/15/22
Giuliani Mario Germano Director Director Sep 07 Sell 42.7 499,500 21,328,650 8,577,140 09/09/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Sep 07 Sell 42.7 498,006 21,264,856 22,426,170 09/09/22
GG 1978 SICAF SIF S.A. - GG St... 10% Owner 10% Owner Aug 25 Sell 44 1,994 87,736 22,924,176 08/29/22
Giuliani Mario Germano Director Director Aug 25 Sell 44 500 22,000 9,076,640 08/29/22
RIGGS RORY B Director Director Aug 09 Sell 43.7294 45,000 1,967,823 376,712 08/11/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Aug 09 Sell 43.92 20,854 915,908 201,114 08/11/22
Coyne Terrance P. EVP & CFO EVP & CFO Aug 01 Sell 43.1909 30,000 1,295,727 970,000 08/03/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jul 28 Sell 43.9676 4,046 177,893 221,968 08/01/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jul 25 Sell 43.28 75,100 3,250,328 226,014 07/27/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Jul 25 Sell 43.12 23,334 1,006,162 07/27/22
RIGGS RORY B Director Director Jun 29 Sell 42.1746 30,000 1,265,238 421,712 06/29/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments Jun 24 Sell 43.1875 23,333 1,007,694 23,334 06/24/22
Reddoch James F. EVP & Chief Scientif.. EVP & Chief Scientific Officer Jun 08 Sell 41.559 100,000 4,155,900 920,800 06/10/22
Reddoch James F. EVP & Chief Scientif.. EVP & Chief Scientific Officer May 27 Sell 41.0801 75,000 3,081,008 1,020,800 05/31/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC May 26 Sell 40.49 100,000 4,049,000 430,000 05/31/22
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC May 23 Sell 40.2677 100,000 4,026,770 530,000 05/25/22
Urist Marshall EVP, Research & Inve.. EVP, Research & Investments May 16 Sell 39.8507 23,333 929,836 46,667 05/16/22
RIGGS RORY B Director Director Mar 29 Sell 38.5887 60,000 2,315,322 601,712 03/30/22
RIGGS RORY B Director Director Mar 17 Sell 39.33 169,089 6,650,270 03/21/22
Fernandez Henry A Director Director Feb 24 Buy 37.4884 32,500 1,218,373 58,200 02/25/22
RIGGS RORY B Director Director Dec 28 Sell 40.16 184,448 7,407,432 592,748 12/30/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Nov 16 Sell 42.51 250,000 10,627,500 630,000 11/18/21
RIGGS RORY B Director Director Nov 16 Sell 42.28 214,389 9,064,367 1,115,645 11/18/21
RIGGS RORY B Director Director Jun 29 Sell 42.17 1,314,912 55,449,839 3,451,258 06/29/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jun 14 Sell 46.47 70,000 3,252,900 240,000 06/14/21
Urist Marshall EVP & Co-Head of R&I EVP & Co-Head of R&I Jun 08 Sell 46.08 33,134 1,526,815 06/08/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Jun 04 Sell 42.11 62,500 2,631,875 1,050,000 06/04/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Apr 16 Sell 42.13 69,822 2,941,601 200,000 04/16/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Apr 14 Sell 42.32 449 19,002 255,898 04/14/21
Lloyd George W. EVP, Investments & G.. EVP, Investments & GC Mar 04 Sell 47.37 125,000 5,921,250 300,000 03/04/21
Reddoch James F. EVP, Research & Inve.. EVP, Research & Investments Mar 04 Sell 47.37 100,000 4,737,000 300,000 03/04/21